

THE INFORMATION IN THIS BOX IS NOT A PART OF THE CONTRACT AND IS FOR COUNTY USE ONLY



Contract Number  
22-1017 A-1

SAP Number

## Department of Public Health

Department Contract Representative	Dominic Correra
Telephone Number	(909) 665-2647
Contractor	California Department of Public Health
Contractor Representative	Paul Kimsey, Ph.D.
Telephone Number	(510) 685-8397
Contract Term	August 1, 2021 through July 31, 2026
Original Contract Amount	\$122,000
Amendment Amount	\$56,598
Total Contract Amount	\$178,598
Cost Center	9300001000
Grant Number (if applicable)	800259

**Briefly describe the general nature of the contract:** Approve and accept Amendment No. 1 to County Contract No. 22-1017, from the California Department of Public Health for Epidemiology and Laboratory Capacity Strengthening Hospital Acquired Infections/Antimicrobial Resistance Program funding, to support expansion of antimicrobial resistance surveillance to enhance testing capacity, increasing the allocation by \$56,598, from \$122,000 to \$178,598, and retroactively extending the period to expend the funding from August 1, 2021 through July 31, 2026.

### FOR COUNTY USE ONLY

Approved as to Legal Form

Adam Ebright, Deputy County Counsel

Date 05/28/2025

Reviewed for Contract Compliance

Date

Reviewed/Approved by Department

Joshua Dugas (May 28, 2025 15:04 PDT)

Joshua Dugas, Director

Date 05/28/2025



TOMÁS J. ARAGÓN, M.D., Dr.P.H.  
Director and State Public Health Officer

State of California—Health and Human Services Agency  
**California Department of Public Health**



GAVIN NEWSOM  
Governor

March 19, 2025

Linda Ward  
Laboratory Director  
San Bernadino County Public Health Laboratory  
150 East Holt Blvd.,  
Ontario, CA 91761

Authority:  
Section 311(c)(1) of the Public  
Health Service Act (42 USC  
243(c)(1)

**ELC SHARP**  
**Award Number - ELCPHLSHARP-06**

American Rescue Plan Act of 2021

Dear Ms. Ward:

This letter covers the ELC Sharp funding through July 31, 2026. California's current surveillance for AR pathogens relies on limited testing performed by local Public Health Laboratories (PHLs), the CDPH Microbial Diseases Laboratory (MDL), and the Washington Regional ARLN laboratory. This ELC Strengthening HAI/AR Program Capacity (SHARP) funding will support expansion of antimicrobial resistance (AR) surveillance in California via screening activities for carbapenemase-producing organisms (CPOs) and *Candida auris*, as well as supporting additional capacity for other optional activities including Whole Genome Sequencing (WGS) for HAI/AR pathogens and establishing capacity for AST of *Neisseria gonorrhoeae*.

CDPH will allocate \$3,816,604.77 to 14 local PHLs that have proposed to provide additional testing for HAI/AR pathogens to build capacity for the AR laboratory network in California. Funding for SHARP activities is covered for the period beginning August 1, 2021 to July 31, 2026. The California Department of Public Health (CDPH) is allocating **\$178,597.82 to San Bernardino County Public Health Laboratory**.

**Funding:**

The ELC funding term for this project is August 1, 2021 to July 31, 2026. CDPH will evaluate spending at the local level in August 2023 and will consider options for possible redirection of funds at that time.

**Allowable Costs:**

---

CDPH Emergency Preparedness Office, MS 7002 • P.O. Box 997377 • Sacramento, CA  
95899-7377  
(916) 650-6416 • (916) 650-6420 FAX  
Internet Address: [www.cdph.ca.gov](http://www.cdph.ca.gov)



Approved funding was based on the initial proposals that were submitted by your laboratory, availability of funds, and alignment of proposed activities with surveillance and testing priorities.

For a detailed listing of allowable costs and activities, please refer to the funding guidance document, Attachment X.

#### **Unallowable Costs:**

The funding associated with the SHARP grant cannot be used for the following costs:

- Research
- Clinical care
- Publicity and propaganda (lobbying):
  - Other than for normal and recognized executive-legislative relationships, no funds may be used for:
    - publicity or propaganda purposes, for the preparation, distribution, or use of any material designed to support or defeat the enactment of legislation before any legislative body.
    - the salary or expenses of any grant or contract recipient, or agent acting for such recipient, related to any activity designed to influence the enactment of legislation, appropriations, regulation, administrative action, or Executive order proposed or pending before any legislative body.

#### **Submission Requirements:**

Complete the attached Workplan and Spend Plan by **06/17/2022** and submit to CDPH utilizing the ELENOR System. See *Attachments 1 and 2*. Your Agency should consider the following when developing your Workplan and Spend Plan:

- If hiring staff from these project funds, develop approximate goals and metrics regarding diversity of staff hired and equity and inclusion activities. Report on progress against those measures will be required.
- Reasonable Milestones and Achieve By dates that accomplish the project mission. Progress on milestones will be evaluated quarterly.
- Spend plan within your proposed budget that specifically support the activities in your workplan and project proposal.

### **Reporting Requirements:**

As a subrecipient of ELC SHARP funding, it will be required to submit reporting documents and requested data. For your convenience, your Contract Manager will issue reminders as these dates get closer through the *Enhanced Laboratory Emergency Network Operations and Response* platform (ELENOR). Training will be provided on the ELENOR system should any county not currently be utilizing it.

1. Quarterly progress reports on status of timelines, goals, and objectives.
2. Performance metrics that will be required by CDC for reporting and/or defined by the CDPH. Due dates will be provided once they are made available.
  - Applicable data may include numbers of screening and/or confirmatory tests performed and breakdown of results for CPO pathogens (including species tested if performing confirmatory testing) and *C. auris*, number of HAI/AR isolates sequenced (WGS) and sequence data uploaded to NCBI, number of *N. gonorrhoeae* isolates submitted for AST (with related result breakdown), and number of tests sent to MDL or the Regional ARLN in Washington.
  - Additional metrics may be requested.

Progress reports must be submitted to CDPH through the ELENOR system following the schedule below. Note, if your workplan or spend plan is under review by CDPH and has not been approved by the progress report due date, you are still required to submit your progress report to CDPH.

<b>Year/Quarter</b>	<b>Reporting Period</b>	<b>Due Date</b>
Year 1/Q4	May 1, 2022 – July 31, 2022	August 15, 2022
Year 1/Q5	August 1, 2022 – October 31, 2022	November 15, 2022
Year 1/Q6	November 1, 2022 – January 31, 2023	February 15, 2022
Year 1/Q7	February 1, 2023 – April 30, 2023	May 15, 2023
Year 1 /Q8	May 1, 2022 – July 31, 2022	August 15, 2023
Year 2 /Q1	August 1, 2023 – October 31, 2023	November 15, 2023
Year 2 /Q2	November 1, 2023 – January 31, 2024	February 15, 2024
Year 2/Q3	February 1, 2024 – April 30, 2024	May 15, 2024
Year 2/Q4 Final	May 1, 2024 – July 31, 2024	August 15, 2024

### **Reimbursement/Invoicing:**

CDPH will reimburse your Agency upon receipt of invoice. In order to receive your reimbursements, please complete and submit your invoice(s) through the ELENOR system. See Attachment 3-Invoice.

1. Payment: Upon receipt of invoice, CDPH will reimburse your Agency for 100% of your total expenditure per invoice.

2. Your Agency must maintain supporting documentation for any expenditures invoiced to CDPH against this source of funding. Documentation should be readily available in the event of an audit or upon request from CDPH. Documentation should be maintained onsite for five years.

Thank you for the time your Agency has and will continue to invest in this initiative to build a strong surveillance network in California for AR pathogens. If you have any questions or need further clarification, please reach out to:

[katemcpherson@internationalrespondersystems.com](mailto:katemcpherson@internationalrespondersystems.com)

Sincerely,

*Paul B. Kimsey Ph.D.*

Paul B. Kimsey, Ph.D.

Deputy Director

California Department of Public Health

California State Public Health Laboratory Director

850 Marina Bay Pkwy

Richmond, CA. 94804

510-412-5846-phone

510-412-5848-fax

### **Attachments**

Attachment 1: Workplan and Progress Report

Attachment 2: Spend Plan and Expenditure Report

Attachment 3: Invoice Template

Attachment 4: HAI Sharp Funding Guidance